|
|
| | BAY-5094 Basic information |
| Product Name: | BAY-5094 | | Synonyms: | BAY-5094;1,3-Benzenedicarboxamide, 4-chloro-N1-[(3,4-difluorophenyl)methyl]-6-fluoro-N3-[4-(1-hydroxy-1-methylethyl)phenyl]- | | CAS: | 2891706-78-6 | | MF: | | | MW: | 476.88 | | EINECS: | | | Product Categories: | | | Mol File: | 2891706-78-6.mol |  |
| | BAY-5094 Chemical Properties |
| Boiling point | 544.812±50.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.396±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 11.539±0.70(predicted) | | form | Solid | | color | White to off-white |
| | BAY-5094 Usage And Synthesis |
| Uses | BAY-5094 is a PPAR gamma (PPARG) inverse agonist. BAY-5094 has oral activity. BAY-5094 can be used in the research of luminal bladder cancer[1]. | | IC 50 | PPAR-γ | | References | [1] Douglas L Orsi, et al. Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists. Bioorg Med Chem. 2023. DOI:10.1016/j.bmc.2022.117130 |
| | BAY-5094 Preparation Products And Raw materials |
|